Literature DB >> 17117442

Quantification of trandolapril and its metabolite trandolaprilat in human plasma by liquid chromatography/tandem mass spectrometry using solid-phase extraction.

Ramakrishna V S Nirogi1, Vishwottam N Kandikere, Wishu Shrivastava, Koteshwara Mudigonda.   

Abstract

A sensitive high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (MS/MS) method was developed and validated for the simultaneous quantification of trandolapril and its metabolite trandolaprilat in human plasma using ramipril as an internal standard. Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M-H]- ions, m/z 429/168 for trandolapril, m/z 401/168 for trandolaprilat and m/z 415/166 for the internal standard. The method exhibited a linear dynamic range of 20-10,000 pg/mL for both trandolapril and trandolaprilat in human plasma. The lower limit of quantification was 20 pg/mL for both trandolapril and its metabolite. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117442     DOI: 10.1002/rcm.2794

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  3 in total

1.  CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.

Authors:  Hao-Jie Zhu; Taimour Y Langaee; Yan Gong; Xinwen Wang; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson; John S Markowitz
Journal:  Eur J Clin Pharmacol       Date:  2016-02-26       Impact factor: 2.953

2.  Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects.

Authors:  Xiaojiao Li; Chang Liu; Min Wu; Hong Zhang; Yanfu Sun; Longmei Cheng; Hong Chen; Chengjiao Liu; Lizhi Yang; Qi Zhang; Yuchen Cao; Jingkai Gu; Yanhua Ding
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

3.  Hptlc method development and validation of trandolapril in bulk and pharmaceutical dosage forms.

Authors:  N Sreekanth; Bahlul Z Awen; Ch Babu Rao
Journal:  J Adv Pharm Technol Res       Date:  2010-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.